Kyprolis Sales On-Track (ONXX) - Jefferies

Jefferies reiterated a Buy rating and $104 price target on Onyx Pharmaceuticals (NASDAQ: ONXX) Wednesday following W-K May data on Kyprolis which shows it is on track to meet Q2 estimates.

Analyst Biren Amin comments, "W-K May data report Kyprolis sales of $13.3M, which potentially translates to actual sales of ~$22M given W-K under-reports actual Kyprolis sales. Assuming June sales are consistent with May, Kyprolis is on-track to meet Q2 estimates (JEF: $65M and cons: $66M), suggesting the launch trajectory remains on a strong track when also factoring in the Pomalyst launch in RRMM."

For an analyst ratings summary and ratings history on Onyx Pharmaceuticals click here. For more ratings news on Onyx Pharmaceuticals click here.

Shares of Onyx Pharmaceuticals closed at $88.80 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies on Five Below (FIVE): 'Our latest channel checks reinforce our view that FIVE's momentum extends well beyond viral Squish trends'
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)